The global large and small-scale bioprocessing market size is likely to be valued at US$94.2 billion in 2026 and is estimated to reach US$217.5 billion by 2033, growing at a CAGR of 12.7% during the forecast period from 2026 to 2033, driven by the expanding production of biologics, vaccines, and advanced cell and gene therapies across the pharmaceutical industry. Rising adoption of single-use bioprocessing technologies and continuous manufacturing is improving production efficiency while reducing contamination risks and operational costs.

Driver - Increasing Use of Biologic Medicines to Propel Advanced Bioprocessing

Rising use of biologic medicines is one of the key drivers for the global market. Monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies all require controlled bioprocessing systems during development and commercial production. As more biologics enter clinical trials and receive regulatory approvals, manufacturers are expanding production capacity and investing in modern bioreactors, filtration systems, and cell culture technologies.

According to the U.S. Food and Drug Administration (FDA), the number of approved cell and gene therapies is expected to rise steadily over the next ten years, while monoclonal antibodies continue to dominate the biologics pipeline. Companies are responding by building new manufacturing facilities. For example, Merck announced the construction of a new biologics manufacturing facility in Delaware in 2025 to strengthen its production capabilities and meet exponential global demand.

High Biotechnology Funding to Push Process Development and Manufacturing

Increasing investments in biotechnology research are creating high demand for advanced bioprocessing equipment. Governments, pharmaceutical companies, and private investors are funding research in biologics, precision medicine, synthetic biology, and advanced therapies. These investments require laboratory-scale and pilot-scale bioprocessing systems before products move to commercial manufacturing. Research organizations are also adopting automated and single-use platforms to speed up process development.

The U.S. National Institutes of Health (NIH) continues to invest billions of dollars annually in biomedical research, supporting innovations that rely heavily on bioprocessing technologies. At the same time, biotechnology companies are extending partnerships with CDMOs to shorten development timelines. This continuous flow of research funding is encouraging suppliers to introduce more flexible, automated, and expandable bioprocessing solutions.

Restraint - Expanding Production May Create Complex Process Control Challenges

Expanding a bioprocess from laboratory level to commercial production remains one of the leading challenges for manufacturers. As production volume increases, maintaining uniform oxygen transfer, nutrient distribution, temperature, and mixing becomes more difficult. Poor process control can reduce product quality, lower cell viability, and increase manufacturing costs. Sensitive mammalian cells are especially vulnerable to mechanical stress caused by large mixing systems.

Researchers continue to study these engineering challenges to improve large-scale manufacturing reliability. A review published in the Journal of Chemical Technology & Biotechnology highlights that oxygen transfer limitations and hydrodynamic stress remain the main barriers when expanding mammalian cell bioprocesses. These technical issues often require additional process optimization, increasing development time before commercial production can begin.

Opportunity - Rising Adoption of Disposable Systems to Simplify Biologics Manufacturing

The surging shift toward single-use bioprocessing technologies delivers significant opportunities for equipment manufacturers. Disposable bioreactors, tubing, bags, and filtration systems reduce cleaning requirements, shorten turnaround time, and lower contamination risks. They also provide flexibility for producing multiple biologics in the same facility. This is especially valuable for CDMOs and companies developing personalized medicines in small production batches.

In April 2025, Thermo Fisher Scientific introduced the 5L DynaDrive Single-Use Bioreactor, extending its DynaDrive platform from research-scale development to commercial manufacturing. The company stated that the platform enables easy scale-up while maintaining process consistency, helping boost biologics development and reducing manufacturing complexity.

Continuous Production Methods to Improve Manufacturing Efficiency

Continuous biomanufacturing is creating new opportunities by replacing traditional batch-based production with uninterrupted processing. Continuous systems improve equipment utilization, reduce production time, and provide more consistent product quality. They also support real-time monitoring and automation, allowing manufacturers to detect process variations early. This approach is becoming very important as biologics demand rises and companies seek more efficient production methods.

Regulatory agencies such as the U.S. FDA have encouraged the adoption of advanced manufacturing technologies, including continuous manufacturing, to improve pharmaceutical quality and supply chain resilience. As digital monitoring tools, Process Analytical Technologies (PAT), and automation continue to advance, continuous bioprocessing is predicted to become a key area of investment across both large- and small-scale manufacturing facilities.

Product Type Insights

Bioreactors/Fermenters are predicted to lead with a share of approximately 33.6% in 2026, as they provide precise control over critical process conditions such as temperature, pH, dissolved oxygen, and nutrient supply. This helps maintain consistent cell growth and improves the quality and yield of biologics, vaccines, enzymes, and other bio-based products. Modern systems also support automation, reducing human error and improving batch-to-batch consistency.

Cell culture products are estimated to be the fastest-growing over the forecast period, as they are essential for manufacturing monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and gene therapies. Every stage of biologics development depends on high-quality culture media, sera, reagents, and supplements to maintain healthy cell growth and achieve reproducible results. The increasing number of biologics and advanced therapy pipelines is further driving demand.

Application Insights

Biopharmaceuticals are anticipated to dominate with a share of nearly 61.4% in 2026, as they require sophisticated bioprocessing equipment throughout research, clinical development, and commercial manufacturing. Products such as monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies cannot be produced efficiently without advanced bioreactors, cell culture systems, filtration technologies, and purification platforms.

Specialty industrial chemicals are expected to remain in the second position in 2026, as industries are now replacing petroleum-based chemical production with microbial fermentation and enzyme-based manufacturing. Bioprocessing enables the production of high-value chemicals with lower energy consumption, reduced greenhouse gas emissions, and improved process sustainability. Governments and manufacturers are also promoting bio-based production to support circular economy goals and reduce dependence on fossil resources.

North America Large and Small-scale Bioprocessing Market Trends

North America is predicted to dominate in 2026 with a global share of approximately 35.9%, as it has the world's most well-established biopharmaceutical manufacturing hub. The region is home to leading biologics manufacturers, CDMOs, research institutes, and bioprocessing technology companies such as Thermo Fisher Scientific, Danaher (Cytiva), Repligen, and Corning. Companies in the region constantly adopt advanced technologies such as single-use bioreactors, continuous bioprocessing, and digital manufacturing, helping improve production efficiency and speed.

Strong support from the U.S. FDA for innovative biologics and advanced manufacturing has also encouraged continuous investments in modern bioprocessing facilities.

U.S. Large and Small-scale Bioprocessing Market Trends

A share of nearly 71.1% is expected to be held by the U.S. in 2026 in North America, as it continues to attract investments in biologics manufacturing and process innovation. Pharmaceutical companies are expanding domestic production capacity for monoclonal antibodies, vaccines, and cell and gene therapies. For example, Thermo Fisher Scientific expanded its biologics manufacturing capabilities through multiple acquisitions and facility investments. The country also benefits from a strong biotechnology start-up culture and close collaboration between academia and industry, fueling the adoption of next-generation bioprocessing platforms.

Asia Pacific Large and Small-scale Bioprocessing Market Trends

Asia Pacific is anticipated to be the fastest-growing region in 2026 with a global share of nearly 33.1%, as governments and private companies are steadily expanding biologics manufacturing capacity to meet rising healthcare demand and reduce dependence on imports. The region has become a preferred destination for biopharmaceutical manufacturing due to low operating costs, skilled scientific talent, and increasing investments in CDMOs. Countries across the region are also strengthening local production of biosimilars, vaccines, and advanced therapies while adopting modern single-use bioprocessing technologies.

China Large and Small-scale Bioprocessing Market Trends

China will likely lead in Asia Pacific in 2026 with a regional share of around 35.7%, as it has built one of the world's fastest-expanding biotechnology hubs. Government support, infrastructure development, and increasing investment in biologics manufacturing have helped domestic companies strengthen their global presence. Companies such as WuXi Biologics continue expanding large-scale manufacturing capabilities, while local biotech firms are signing a surging number of international licensing and development agreements.

India Large and Small-scale Bioprocessing Market Trends

In 2026, India is projected to account for a regional share of approximately 20.9% in Asia Pacific, as the country is strengthening its position in vaccine production, biosimilars, and contract biomanufacturing. Government initiatives promoting biotechnology research and domestic biomanufacturing, together with expanding investments by the country’s pharmaceutical companies, are increasing demand for modern bioprocessing equipment. India also benefits from a large pool of skilled biotechnology professionals and is becoming an attractive destination for global contract manufacturing of biologics and vaccines.

Europe Large and Small-scale Bioprocessing Market Trends

Europe will witness steady growth over the forecast period with a global share of nearly 16.7% in 2026 globally, owing to its well-established pharmaceutical industry, advanced manufacturing standards, and continuous investments in biologics production. Countries across the region are increasing the use of continuous manufacturing, process automation, and single-use technologies to improve production efficiency. The presence of leading bioprocessing companies such as Sartorius and Merck KGaA, along with supportive regulatory guidance from the European Medicines Agency (EMA), has encouraged manufacturers to modernize their facilities and expand biologics production.

Germany Large and Small-scale Bioprocessing Market Trends

Germany is anticipated to register a substantial regional share of approximately 38.9% in 2026 in Europe, as it combines advanced engineering expertise with a well-established biotechnology industry. The country hosts global leaders such as Sartorius and Merck KGaA, which continue to invest in single-use systems, filtration technologies, and digital bioprocessing solutions. Strong collaboration between universities, research institutes, and industry also supports continuous innovation in biologics manufacturing and process development.

U.K. Large and Small-scale Bioprocessing Market Trends

A regional share of around 16.3% is predicted to be held by the U.K. in 2026 in Europe, supported by its leadership in cell and gene therapy manufacturing and translational research. Organizations such as the Cell and Gene Therapy Catapult continue to help companies expand manufacturing processes from laboratory to commercial production. The country is also witnessing increased collaboration between universities, biotechnology companies, and manufacturers to accelerate the commercialization of advanced therapies, creating sustained demand for both large- and small-scale bioprocessing technologies.

The global large and small-scale bioprocessing market is moderately consolidated with a handful of multinational companies controlling the largest share of advanced bioprocessing equipment and consumables. Large global players such as Thermo Fisher Scientific, Danaher (Cytiva and Pall), Merck KGaA (MilliporeSigma), Sartorius, Lonza, Corning, Eppendorf, and Repligen compete by delivering complete bioprocessing solutions rather than standalone products. Their portfolios include cell culture media, bioreactors, filtration systems, chromatography, sensors, process analytics, and digital monitoring software.

Competition in large-scale bioprocessing is focused on manufacturing reliability, high-yield production, and regulatory compliance. Leading suppliers continue to broaden production facilities for bioprocess consumables and filtration technologies to meet rising biologics demand. Single-use technologies have become one of the strongest competitive differentiators across both large- and small-scale operations. Suppliers are investing heavily in disposable bioreactors, tubing assemblies, filtration devices, and sensors as biopharmaceutical manufacturers want quick facility setup, low contamination risk, and high manufacturing flexibility.

Key Industry Developments:

• In September 2025, Thermo Fisher Scientific completed the acquisition of Solventum's Purification & Filtration business. The company stated that the addition of membrane filtration and purification technologies would enhance its Life Sciences Solutions segment and provide a broad portfolio for biopharmaceutical manufacturing customers worldwide.
• In July 2025, Thermo Fisher Scientific acquired Sanofi's sterile fill-finish and packaging facility in Ridgefield, New Jersey. The acquisition expanded Thermo Fisher's U.S. biologics manufacturing network and strengthened its Contract Development and Manufacturing (CDMO) capabilities for commercial biopharmaceutical production.
• In March 2025, Repligen acquired four Process Analytical Technology (PAT) assets from 908 Devices. The acquisition expanded Repligen's real-time bioprocess monitoring capabilities, enabling improved analytical control for upstream and downstream biologics manufacturing and supporting the industry's shift toward automated and continuous bioprocessing.